Mutational spectrum of DNA damage and mismatch repair genes in prostate cancer

Area of Science:

• Oncology
• Genetics
• Immunology

Background:

• Prostate cancer is linked to genetic defects in DNA damage repair (DDR) and mismatch repair (MMR) genes.
• Specific gene alterations in homologous recombination repair (HRR) and MMR pathways are associated with higher risk and more severe prostate cancer.
• DDR is vital for immune cell development, but its imbalance can lead to mutations, cell death, and impact tumor immunity.

Purpose of the Study:

• To review the mutation spectrum and clinical significance of DDR mechanisms, including HRR and MMR abnormalities in prostate cancer.
• To explain how understanding these genetic alterations is evolving patient management strategies.
• To highlight the importance of mutational genetic testing for targeted therapies.

Main Methods:

• Literature review of studies on genetic defects in prostate cancer.
• Analysis of the role of HRR and MMR gene mutations in prostate cancer development and progression.
• Examination of the impact of DDR anomalies on tumor immunity and patient response to immunotherapy.

Main Results:

• Defects in HRR genes (e.g., BRCA2, ATM) and MMR genes (e.g., MLH1, MSH2) are prevalent in prostate cancer, particularly in metastatic cases.
• DDR pathway dysfunction can promote tumor growth and aberrant immune responses.
• Altered MMR genes may predict a significant benefit from immunotherapy.

Conclusions:

• Genetic testing for DDR and MMR mutations is indicated for prostate cancer patients, especially those with advanced disease or specific histologies.
• Understanding these genetic alterations is crucial for personalized treatment approaches, including immunotherapy.
• The evolving knowledge of HRR and MMR abnormalities is transforming prostate cancer patient management.